We are developing an early breast cancer detection lateral flow assay (LFA) based on a dual-biomarker approach, with a focus on clinically relevant biomarkers, analytical performance, and real-world usability.

We are looking for a hands-on LFA/IVD development professional who can contribute across the complete assay development cycle—from antibody and biomarker evaluation through conjugation, membrane optimization, sensitivity tuning, assay troubleshooting, and translational scale-up.

This role is suited for someone with practical experience in lateral flow assay development, rather than purely academic or theoretical exposure.

What We Are Looking For The ideal candidate will be a hands-on assay developer who is comfortable working at the bench and solving experimental problems.

You should be able to move from:

Biomarker & antibody selection → conjugation → membrane optimization → prototype development → sensitivity/specificity optimization → clinical sample evaluation → scale-up with a strong focus on reproducibility, analytical performance, and practical product development.

Required Qualifications

- M.Sc./M.Tech./Ph.D. in Biotechnology, Biochemistry, Microbiology, Life Sciences, Biomedical Sciences, or a related discipline.
- 2–6 years of hands-on experience in LFA/rapid diagnostic assay development.
- Strong practical understanding of lateral flow assay components and development workflows.
- Experience with antibody screening, pairing, conjugation, membrane selection, strip assembly, and assay optimization.
- Experience working with serum/plasma or other biological matrices will be highly preferred.
- Strong understanding of immunoassay principles and diagnostic assay development.
- Ability to independently design experiments, troubleshoot assay performance, and interpret experimental data.

Preferred Experience





Candidates with experience in one or more of the following will be strongly preferred:

- Dual/multiplex biomarker LFA development
- Early cancer or oncology diagnostics
- Breast cancer biomarkers
- Quantitative or semi-quantitative LFA platforms
- Gold nanoparticle or latex-based detection systems
- Recombinant antibody / monoclonal antibody evaluation
- Clinical sample testing
- ELISA/CLIA correlation studies
- IVD product development and analytical validation
- Transition of prototype assays toward manufacturing
- ISO 13485 / IVD development environments

Key Responsibilities

1. LFA Assay Development

- The dual-biomarker assay architecture will be developed and optimized for early breast cancer detection.
- Suitable antibody pairs, recombinant proteins/antigens, and detection systems will be evaluated.
- Capture and detection antibody combinations will be screened for sensitivity, specificity, and signal-to-background performance.
- Assay conditions including sample volume, reaction time, buffer composition, and test format will be optimized.

2.

Antibody

Conjugation & Detection Chemistry

- Gold nanoparticle/latex or other suitable reporter conjugation approaches will be developed and optimized.
- Antibody-to-particle conjugation conditions, loading, stability, and conjugate performance will be evaluated.
- Detection chemistry will be optimized to achieve strong signal generation while minimizing nonspecific background.

3. Membrane & Strip Optimization

- Nitrocellulose membranes, conjugate pads, sample pads, absorbent pads,



and backing materials will be evaluated.
- Membrane selection and running characteristics will be optimized based on assay requirements.
- Blocking, surfactant, buffer, and pad-treatment conditions will be systematically optimized.
- Test-line and control-line performance will be evaluated and optimized.

4. Sensitivity, Specificity & Analytical Performance

- The assay will be optimized for clinically meaningful analytical sensitivity and specificity.
- Limit of detection (LoD), agile range, precision, reproducibility, interference, cross-reactivity, and matrix effects will be evaluated.
- Individual biomarker performance and combined dual-biomarker performance will be assessed.
- Assay failure modes and sources of variability will be systematically investigated.

5. Biological Sample & Translational Development

- Assay performance using relevant clinical sample matrices, particularly serum/plasma, will be evaluated.
- Sample preparation and matrix compatibility will be optimized where required.
- Correlation with established reference methods such as ELISA/CLIA will be investigated.
- The candidate will support transition from laboratory prototype to a robust, reproducible diagnostic product.

Pay: ₹600,000.00 - ₹2,500,000.00 per year

Benefits

- Flexible schedule
- Provident Fund

Application Question(s):
- how many year of expereince in Dual/multiplex biomarker LFA development?
- have you ever worked on Early cancer or oncology diagnostics?
- do you have Experience with antibody screening, pairing, conjugation, membrane selection, strip assembly, and assay optimization.? if yes how many years?
- have you ever worked on Membrane & Strip Optimization? if yes how many years?
- do you have understanding of Sensitivity, Specificity & Analytical Performance? if yes please explain here?

Work Location: In person

📌 LFA Development Scientist – Early Breast Cancer Diagnostics (South West Delhi)
🏢 Startup Khata
📍 South West Delhi